Literature DB >> 19880063

Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009.

Yok-Lam Kwong1, Benjamin O Anderson, Ranjana Advani, Won-Seog Kim, Alexandra M Levine, Soon-Thye Lim.   

Abstract

T-cell and natural-killer (NK)-cell lymphomas are neoplasms with geographical variations in frequencies. T-cell lymphomas are more prevalent in Asia than in Europe and North America, and NK-cell lymphomas occur almost exclusively in Asia and South America. These low frequencies mean that the diagnosis and optimum treatment of patients with T-cell and NK-cell lymphomas have not been studied prospectively in randomised controlled trials. Because T-cell and NK-cell lymphomas are more prevalent in Asia, the establishment of management recommendations by Asian oncologists in collaboration with international experts is pertinent. This review outlines guidelines commensurate with different levels of health-care resources and expertise. Consensus statements were formulated for diagnosis, staging, follow-up, and treatment approaches in patients with T-cell and NK-cell lymphomas--aimed at unifying the design of studies and interpretation of results. For patients not in clinical trials, consensus opinions offer useful guidelines on optimum management.

Entities:  

Mesh:

Year:  2009        PMID: 19880063     DOI: 10.1016/S1470-2045(09)70265-7

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  26 in total

1.  Romidepsin: in the treatment of T-cell lymphoma.

Authors:  Lily P H Yang
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

2.  Combined therapy in untreated patients improves outcome in nasal NK/T lymphoma: results of a clinical trial.

Authors:  Agustin Avilés; Natividad Neri; Raúl Fernández; Judith Huerta-Guzmán; Maria-Jesus Nambo
Journal:  Med Oncol       Date:  2013-06-25       Impact factor: 3.064

3.  A novel prognostic model for extranodal natural killer/T-cell lymphoma.

Authors:  Jia-Jia Huang; Ying-Jie Zhu; Yi Xia; Wei Zhao; Tong-Yu Lin; Wen-Qi Jiang; Hui-Qiang Huang; Zhi-Ming Li
Journal:  Med Oncol       Date:  2011-07-23       Impact factor: 3.064

4.  Somatic mutations in KMT2D and TET2 associated with worse prognosis in Epstein-Barr virus-associated T or natural killer-cell lymphoproliferative disorders.

Authors:  Li-Min Gao; Sha Zhao; Wen-Yan Zhang; Mi Wang; Hui-Fang Li; Anle Lizaso; Wei-Ping Liu
Journal:  Cancer Biol Ther       Date:  2019-07-16       Impact factor: 4.742

Review 5.  Current and future management of NK/T-cell lymphoma based on clinical trials.

Authors:  Motoko Yamaguchi
Journal:  Int J Hematol       Date:  2012-10-17       Impact factor: 2.490

6.  Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type.

Authors:  Li Yang; Hong Liu; Xiao-hong Xu; Xin-feng Wang; Hong-ming Huang; Wen-yu Shi; Sheng-hua Jiang
Journal:  Med Oncol       Date:  2013-09-24       Impact factor: 3.064

Review 7.  Novel findings from the Asian Lymphoma Study Group: focus on T and NK-cell lymphomas.

Authors:  Jason Yongsheng Chan; Soon Thye Lim
Journal:  Int J Hematol       Date:  2018-01-29       Impact factor: 2.490

8.  Aggressive natural killer-cell leukemia with jaundice and spontaneous splenic rupture: a case report and review of the literature.

Authors:  Li-min Gao; Wei-ping Liu; Qun-pei Yang; Hui-fang Li; Jun-jie Chen; Yuan Tang; Yan Zou; Dian-Ying Liao; Yan-mei Liu; Sha Zhao
Journal:  Diagn Pathol       Date:  2013-03-11       Impact factor: 2.644

9.  Variation in dicer gene is associated with increased survival in T-cell lymphoma.

Authors:  Xi Li; Xiaobo Tian; Bo Zhang; Yanqi Zhang; Jieping Chen
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

10.  Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia.

Authors:  Hamilton L Gimenes-Teixeira; Antonio R Lucena-Araujo; Guilherme A Dos Santos; Dalila L Zanette; Priscila S Scheucher; Luciana C Oliveira; Leandro F Dalmazzo; Wilson A Silva-Júnior; Roberto P Falcão; Eduardo M Rego
Journal:  Exp Hematol Oncol       Date:  2013-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.